Is prostate cancer common?

Yes. Prostate cancer is the most common cancer among men in the United States. It is also the second leading cause of cancer death among men in the country.

The numbers behind that are large. For 2026 the American Cancer Society projects about 333,830 new cases and 36,320 deaths, and SEER, the National Cancer Institute's cancer statistics program, publishes that projection on its prostate page. Prostate cancer alone accounts for 15.8% of all new cancer diagnoses in the US, across both sexes.

Put another way: about 13.2% of men will be diagnosed with prostate cancer at some point in life. That is roughly 1 in 8.

Common, but usually not the thing that ends a life

Notice the gap between those two figures. Roughly 334,000 diagnoses. Roughly 36,000 deaths.

That gap is the most important fact about this disease. Even though prostate cancer is common, it usually grows very slowly. Because it often grows so slowly, finding and treating it before symptoms appear may not always improve a man's health or help him live longer.

Survival figures show the same thing. Among men diagnosed from 2016 through 2022, SEER reports 5-year relative survival of 98.2% overall. For cancer still confined to the prostate, and for cancer that has reached nearby tissue, that figure is 100.0%. Most cases are caught in those groups: 69% localized and 14% regional.

The picture changes when it has spread to distant parts of the body. There, 5-year relative survival is 40.1%. That group is 9% of diagnoses, and it accounts for most of the deaths.

Who it happens to

Age is the dominant factor. The largest share of diagnoses falls between ages 65 and 74. Prostate cancer is uncommon in younger men.

Risk is not spread evenly. Black men and men with a father or brother who had the disease face higher risk, as do men with inherited BRCA changes. For those groups, testing discussions often start earlier.

A trend worth knowing

SEER reports that new prostate cancer diagnoses rose an average of 2.7% per year from 2014 to 2023. Over a similar span, death rates fell an average of 0.8% per year from 2015 to 2024.

Rising diagnoses with falling deaths is a pattern that can mean several things at once, including more testing, more cases found that were never going to cause harm, and better treatment for the cases that would.

What this means if you are deciding about screening

"Common" and "dangerous" are not the same word, and prostate cancer is a case where they come apart.

The practical question is not whether prostate cancer is common. It is whether finding a slow-growing one early would help you. If you have questions about your own risk, or about whether screening is right for you, your healthcare team can help.

A test called the prostate-specific antigen (PSA) test is one tool related to prostate cancer screening, and your team can explain the choices and what they may mean for you. Worth asking about at the same visit: active surveillance, which means watching a low-risk cancer closely instead of treating it right away. Knowing that option exists changes what a diagnosis would actually mean for you.